(4R,10bR)-4-methyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (4R,10bR)-4-methyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride
• 英文别名: (4R,10bR)-1,3,4,10b-tetrahydro-4-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride；(4R,10bR)-1,3,4,10b-tetrahydro-4-methyl-7-trifluoromethyl-pyrazino[2,1-a]isoindol-6(2H)-one hydrochloric acid salt；(4R,10bR)-4-methyl-7-(trifluoromethyl)-2,3,4,10b-tetrahydro-1H-pyrazino[1,2-b]isoindol-6-one;hydrochloride
• 化学式: C₁₃H₁₃F₃N₂O*ClH
• 分子量: 306.715
• InChiKey: JFPNFHMZPBRSBA-QJVKKXMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.62
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4R,10bR)-4-methyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 、 (4R,10bS)-4-methyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 、 二碳酸二叔丁酯 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 生成 N-(t-butoxycarbonyl)-(4R,10bS)-1,3,4,10b-tetrahydro-4-methyl-7-trifluoromethoxypyrazino[2,1-a]isoindol-6(2H)-one 、 N-(t-butoxycarbonyl)-(4R,10bS)-1,3,4,10b-tetrahydro-4-methyl-7-trifluoromethoxypyrazino[2,1-a]isoindol-6(2H)-one
  参考文献：
  名称：

  Modulators of serotonin receptors

  摘要：

  本发明提供了血清素受体调节剂，包含这些调节剂的药物组合物以及治疗与血清素受体调节相关的各种疾病、症状和疾患的方法，例如：代谢性疾病，包括但不限于肥胖、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、恐慌症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。

  公开号：

  US20050080074A1
• 作为产物：
  描述：

  2-三氟甲基苯甲酰氯 在 palladium on activated charcoal 盐酸 、 四甲基乙二胺 、 氢气 、 仲丁基锂 、 sodium acetate 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 为溶剂， -78.0~100.0 ℃ 、551.58 kPa 条件下， 反应 125.5h， 生成 (4R,10bR)-4-methyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride
  参考文献：
  名称：

  Discovery of (R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a Selective, Orally Active Agonist of the 5-HT_2C Receptor

  摘要：

  Robust pharmaceutical treatment of obesity has been limited by the undesirable side-effect profile of currently marketed therapies. This paper describes the synthesis and optimization of a new class of pyrazinoisoindolone-containing, selective 5-HT2C agonists as antiobesity agents. Key to optimization of the pyrazinoisoindolone core was the identification of the appropriate substitution pattern and functional groups which led to the discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one (58), a 5-HT2C agonist with > 300-fold functional selectivity over 5-HT2B and > 70-fold functional selectivity over 5-HT2A. Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.

  DOI：

  10.1021/jm0612968

文献信息

• [EN] MODULATORS OF SEROTONIN RECEPTORS<br/>[FR] MODULATEURS DES RECEPTEURS DE LA SEROTONINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005035533A1

  公开（公告）日：2005-04-21

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂、含有这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病症和疾患的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• MODULATORS OF SEROTONIN RECEPTORS
  申请人：Wacker A. Dean

  公开号：US20070213337A1

  公开（公告）日：2007-09-13

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impaired glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂，包含这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病况和障碍的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、惊恐障碍、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；和使用这些化合物和组合物治疗胃肠道疾病。
• US7244843B2
  申请人：——

  公开号：US7244843B2

  公开（公告）日：2007-07-17
• US7812024B2
  申请人：——

  公开号：US7812024B2

  公开（公告）日：2010-10-12
• Discovery of (<i>R</i>)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-<i>a</i>]isoindol- 6(2<i>H</i>)-one, a Selective, Orally Active Agonist of the 5-HT_2C Receptor
  作者：Dean A. Wacker、Jeffrey G. Varnes、Sarah E. Malmstrom、Xueying Cao、Chen-Pin Hung、Thao Ung、Ginger Wu、Ge Zhang、Eva Zuvich、Michael A. Thomas、William J. Keim、Mary Jane Cullen、Kenneth W. Rohrbach、Qinling Qu、Rangaraj Narayanan、Karen Rossi、Evan Janovitz、Lois Lehman-McKeeman、Mary F. Malley、James Devenny、Mary Ann Pelleymounter、Keith J. Miller、Jeffrey A. Robl

  DOI：10.1021/jm0612968

  日期：2007.3.1

  Robust pharmaceutical treatment of obesity has been limited by the undesirable side-effect profile of currently marketed therapies. This paper describes the synthesis and optimization of a new class of pyrazinoisoindolone-containing, selective 5-HT2C agonists as antiobesity agents. Key to optimization of the pyrazinoisoindolone core was the identification of the appropriate substitution pattern and functional groups which led to the discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one (58), a 5-HT2C agonist with > 300-fold functional selectivity over 5-HT2B and > 70-fold functional selectivity over 5-HT2A. Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.